STERIS Plc Experiences Valuation Adjustment Amid Competitive Pharmaceuticals Landscape

STERIS Plc (Ireland), a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a valuation adjustment. The company currently presents a P/E ratio of 28, alongside a price-to-book value of 3.00. Its EV to EBIT stands at 21.16, while the EV to EBITDA is recorded at 14.62. The PEG ratio is noted at 2.16, and the dividend yield is 1.12%. Key performance indicators include a return on capital employed (ROCE) of 12.54% and a return on equity (ROE) of 10.82%. In comparison to its peers, STERIS Plc's valuation metrics reflect a competitive stance within the industry. For instance, IDEXX Laboratories, Inc. shows a significantly higher P/E ratio, while GE Healthcare Technologies, Inc. offers a more favorable EV to EBITDA ratio. Other competitors like ResMed, Inc. and Agilent Technologies, Inc. also present varying metrics that highlight the diverse valuation landscape in the sector. Overall, STERIS Plc's recent evaluation revision underscores its positioning amid a dynamic market environment.